Bayforest Capital LTD Apellis Pharmaceuticals, Inc. Transaction History
Bayforest Capital LTD
- $210 Billion
- Q3 2025
A detailed history of Bayforest Capital LTD transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Bayforest Capital LTD holds 20,853 shares of APLS stock, worth $431,448. This represents 0.22% of its overall portfolio holdings.
Number of Shares
20,853
Previous 56,639
63.18%
Holding current value
$431,448
Previous $980 Million
51.87%
% of portfolio
0.22%
Previous 0.43%
Shares
4 transactions
Others Institutions Holding APLS
# of Institutions
302Shares Held
134MCall Options Held
2.97MPut Options Held
623K-
Avoro Capital Advisors LLC New York, NY12.2MShares$253 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$246 Million17.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$210 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.75MShares$202 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.98MShares$186 Million0.03% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.27B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...